CDK4 and neoplasm: In contrast, combining CDK4/6 inhibitors can cause cell arrest in the G1 phase to increase olaparib-induced DNA damage in the G2 phase, strongly inhibit olaparib resistance, and improve anti-tumor efficacy (Zhu et al., 2021a).